A New Model for Eye Disease

Information

  • Research Project
  • 7290925
  • ApplicationId
    7290925
  • Core Project Number
    R44EY015335
  • Full Project Number
    5R44EY015335-04
  • Serial Number
    15335
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/2004 - 20 years ago
  • Project End Date
    9/29/2009 - 15 years ago
  • Program Officer Name
    GOLDMAN, STEPHEN
  • Budget Start Date
    9/30/2007 - 17 years ago
  • Budget End Date
    9/29/2009 - 15 years ago
  • Fiscal Year
    2007
  • Support Year
    4
  • Suffix
  • Award Notice Date
    9/18/2007 - 17 years ago

A New Model for Eye Disease

[unreadable] DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are the two leading causes of blindness in adults in the industrialized world. Both conditions involve vascular abnormalities, proliferation and leakage of new blood vessels. Retinopathy of prematurity (ROP) is a major cause of newborn blindness in premature infants maintained by oxygen supplementation during the postnatal period. This disease involves intense neovascularization of the retina and leads to retinal detachment. Another cause of blindness is corneal neovascularization, which often results from injury and infection in the cornea. Current mammalian models for ocular neovascularization require lengthy, tedious surgical manipulation and do not always result in improved vision; an alternative rapid, less invasive animal model for studying the process of ocular neovascularization and assessing drug effects will facilitate identification of new therapeutics. Phase I research validated zebrafish as a model for vascularization of the eye. Phase II research will develop a zebrafish model for ocular vascularization that can be used to screen drugs that would be effective in treating debilitating diseases involving neovascularization. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL EYE INSTITUTE
  • Activity
    R44
  • Administering IC
    EY
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    158186
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    867
  • Ed Inst. Type
  • Funding ICs
    NEI:158186\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PHYLONIX PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES